A. Aruga, S. Shu, and A. E. Chang, Tumor-specific granulocyte/ macrophage colony-stimulating factor and interferon-gamma secretion is associated with in vivo therapeutic efficacy of activated tumor-draining lymph node cells, Cancer Immunol Immunother, vol.41, p.317, 1995.

R. J. Barth, J. J. Mule, P. J. Spiess, and S. A. Rosenberg, Interferongamma and tumor necrosis factor have a role in tumor regression mediated by murine CD8 + tumor-infiltrating lymphocytes, J Exp Med, vol.173, p.647, 1991.

C. Becker, H. Pohla, B. Frankenberger, T. Schuler, M. Assenmacher et al., Adoptive tumor therapy with T lymphocytes enriched through an IFN-gamma capture assay, Nat Med, vol.7, p.1159, 2001.

H. Benlalam, N. Labarrie`re, B. Linard, L. Derre, E. Diez et al., Comprehensive analysis of the frequency of recognition of melanoma associated antigen (MAA) by CD8 melanoma infiltrating lymphocytes (TIL): implications for immunotherapy, Eur J Immunol, vol.31, 2001.
URL : https://hal.archives-ouvertes.fr/inserm-02482156

R. O. Dillman, R. K. Oldham, N. M. Barth, R. J. Cohen, D. R. Minor et al., Continuous interleukin-2 and tumor-infiltrating lymphocytes as treatment of advanced melanoma. A national biotherapy study group trial, Cancer, vol.68, p.1, 1991.

J. F. Fonteneau, L. Drean, E. , L. Guiner, S. Gervois et al., Heterogeneity of biologic responses of melanoma-specific CTL, J Immunol, vol.159, p.2831, 1997.

P. S. Goedegebuure, L. M. Douville, H. Li, G. C. Richmond, D. D. Schoof et al., Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study, J Clin Oncol, vol.13, p.1939, 1995.

L. Granziero, S. Krajewski, P. Farness, L. Yuan, M. K. Courtney et al., Adoptive immunotherapy prevents prostate cancer in a transgenic animal model, Eur J Immunol, vol.29, p.1127, 1999.

P. D. Greenberg, Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells, Adv Immunol, vol.49, p.281, 1991.

H. L. Hanson, D. L. Donermeyer, H. Ikeda, J. M. White, V. Shankaran et al., , 2000.

, Eradication of established tumors by CD8 + T cell adoptive immunotherapy, Immunity, vol.13, p.265

H. E. Heslop, C. Y. Ng, C. Li, C. A. Smith, S. K. Loftin et al., Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes, Nat Med, vol.2, p.551, 1996.

K. Hung, R. Hayashi, A. Lafond-walker, C. Lowenstein, D. Pardoll et al., The central role of CD4(+) T cells in the antitumor immune response, J Exp Med, vol.188, p.2357, 1998.

Y. Itoh and R. N. Germain, Single cell analysis reveals regulated hierarchical T cell antigen receptor signaling thresholds and intraclonal heterogeneity for individual cytokine responses of CD4 + T cells, J Exp Med, vol.186, p.757, 1997.

F. Jotereau, M. C. Pandolfino, D. Boudart, E. Diez, B. Dreno et al., High-fold expansion of human cytotoxic T-lymphocytes specific for autologous melanoma cells for use in immunotherapy, J Immunother, vol.10, p.405, 1991.

T. Jung, U. Schauer, C. Heusser, C. Neumann, and C. Rieger, Detection of intracellular cytokines by flow cytometry, J Immunol Methods, vol.159, p.197, 1993.

Y. Kawakami, S. Eliyahu, C. Jennings, K. Sakaguchi, X. Kang et al., Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression, J Immunol, vol.154, p.3961, 1995.

S. Matsui, J. D. Ahlers, A. O. Vortmeyer, M. Terabe, T. Tsukui et al., A model for CD8 + CTL tumor immunosurveillance and regulation of tumor escape by CD4 T cells through an effect on quality of CTL, J Immunol, vol.163, p.184, 1999.

S. Mitsuma, H. Yoshizawa, K. Ito, H. Moriyama, M. Wakabayashi et al., Adoptive immunotherapy mediated by anti-TCR/IL-2-activated tumour-draining lymph node cells, Immunology, vol.83, p.45, 1994.

D. Mumberg, P. A. Monach, S. Wanderling, M. Philip, A. Y. Toledano et al., CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma, Proc Natl Acad Sci, vol.97, issue.5, p.2397, 1999.

, Proc Natl Acad Sci, vol.96, p.8633

M. C. Pandolfino, N. Labarriere, M. H. Tessier, A. Cassidanius, S. Bercegeay et al., High-scale expansion of melanoma reactive TIL by a polyclonal stimulus: predictability and relation with disease advancement, Cancer Immunol Immunother, vol.50, p.134, 2001.
URL : https://hal.archives-ouvertes.fr/inserm-02482159

S. A. Rosenberg, B. S. Packard, P. M. Aebersold, D. Solomon, S. L. Topalian et al., Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma, New Engl J Med, vol.319, p.1676, 1988.

S. A. Rosenberg, P. Spiess, and R. Lafreniere, A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes, Science, vol.233, p.1318, 1986.

S. A. Rosenberg, J. R. Yannelli, J. C. Yang, S. L. Topalian, . Schwartzentruber et al., Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin-2, 1994.

, J Natl Cancer Inst, vol.86, p.1159

M. A. Roskrow, N. Suzuki, Y. Gan, J. W. Sixbey, C. Y. Ng et al., Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease, Blood, vol.91, p.2925, 1998.

V. Shankaran, H. Ikeda, A. T. Bruce, J. M. White, P. E. Swanson et al., IFN-gamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity, Nature, vol.410, p.1107, 2001.

C. T. Siegel, K. Schreiber, S. C. Meredith, G. B. Beck-engeser, D. W. Lancki et al., Enhanced growth of primary tumors in cancer-prone mice after immunization against the mutant region of an inherited oncoprotein, J Exp Med, vol.191, p.1945, 2000.

M. H. Tessier, M. C. Pandolfino, F. Jotereau, D. Boudart, P. Litoux et al., Home therapy with autologous tumourinfiltrating lymphocytes and subcutaneous interleukin-2 in metastatic melanoma, 1996.

R. E. Toes, F. Ossendorp, R. Offringa, and C. J. Melief, CD4 T cells and their role in antitumor immune responses, vol.32, pp.735-763, 1999.

, J Exp Med, vol.189, p.753